



10658834 - GAU: 1647

Sheet 1 of 3

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1631

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2004/0081635	04/29/04	Cummins et al.	424	85.6	10/22/03
	AB	2007/0172459	07/26/07	Gantier et al.	424	85.5	02/13/07
	AC	4,462,985	07/31/84	Cummins, Jr.	424	85.6	09/07/82
	AD	4,497,795	02/05/85	Cummins	424	85.6	12/13/82
	AE	4,820,514	04/11/89	Cummins	424	85.6	12/30/85
	AF	4,820,515	04/11/89	Cummins	424	85.6	01/04/85
	AG	5,017,371	05/21/91	Cummins	424	85.4	01/06/88
	AH	5,019,382	05/28/91	Cummins, Jr.	424	85.7	01/17/90
	AI	5,215,741	06/01/93	Young et al.	424	85.6	10/30/90
	AJ	5,817,307	10/06/98	Cummins	424	85.4	06/07/95
	AK	5,824,300	10/20/98	Cummins	424	85.7	06/07/95
	AL	5,830,456	11/03/98	Cummins	424	85.7	09/13/94
	AM	5,846,526	12/08/98	Cummins	424	85.7	06/07/95
	AN	5,882,640	03/16/99	Cummins	424	85.7	06/07/95
	AO	5,910,304	06/08/99	Cummins	424	85.7	04/28/92
	AP	5,997,858	12/07/99	Tovey et al.	424	85.4	05/09/97
	AQ	6,207,145	03/27/01	Tovey	424	85.4	05/09/97
	AR	6,299,872	10/09/01	Albrecht et al.	424	85.7	05/02/00
	AS	6,346,243	02/12/02	Brod	424	85.4	05/19/99
	AT	6,361,769	03/26/02	Tovey	424	85.4	05/09/97
	AU	6,387,365	05/14/02	Albrecht et al.	424	85.4	05/19/95
	AV	6,461,605	10/08/02	Cutler et al.	424	85.7	03/22/02
	AW	6,479,258	11/12/02	Short	435	69.1	01/31/00
	AX	6,482,613	11/19/02	Goeddel et al.	435	69.51	01/19/88
	AY	6,485,480	11/26/02	Brewitt	604	500	02/07/00
	AZ	6,884,411	04/26/05	Tarro et al.	424	85.7	01/04/99
	BA	6,946,125	09/20/05	Rahal	424	85.4	08/23/01

Examiner Signature /Elly Gerald Stoica/	Date Considered 11/20/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EGS/

Sheet 2 of 3

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1631

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	BB	05/003157	01/13/05	WIPO				
	BC	06/024547	03/09/06	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	BD	Callard and Gearing, <i>The Cytokine Facts Book</i> , Academic Press, San Diego, pgs. 157-158, (1994).
	BE	Fumero, S., "Belerofon: a Long-lasting and Orally Available Interferon Alpha" (Meeting Abstract) <i>Third Annual Optimizing Protein and Antibody Therapeutics, Pioneering New Frontiers</i> (January 10, 2007) http://www.chi-peptalk.com/06_PTT.asp
	BF	Martin, P., "Beyond the Next Generation of Therapeutic proteins," October 2006, http://www.biotech-online.com/artimg/a20062123243425.PDF (accessed on January 11, 2007) (3 pages).
	BG	Martin, P., "Next Generation Products and Prospects for the Oral Delivery of Proteins" (Meeting Abstract) <i>Fourth Annual Protein Process Development</i> (January 11, 2007). http://www.chi-peptalk.com/06_Ppd.asp
	BH	Martin, P., "The Market for Therapeutic Proteins: New Business Opportunities" (Meeting Abstract) <i>Second Annual Advancing Protein Therapeutics, Engineering the Next Generation of Proteins for Therapeutics</i> (January 13, 2006). http://www.chi-peptalk.com/pttn2006.asp
	BI	Media Release: "In Vivo Studies Provide Hope for Orally Available Protein Therapeutics" Paris, France and Boston, Massachusetts (USA) April 26, 2006 http://www.prnewswire.co.uk/cgi/news/release?id=169343 (accessed on January 8, 2007) (3 pages)
	BJ	Media Release: "Nautilus Biotech and Angel Biotechnology Sign Agreement to Manufacture Belerofon(R) (Improved Alpha Interferon) for Phase I Clinical Trials" Paris, France and Northumberland, England December 6, 2004 http://www.prnewswire.co.uk/cgi/news/release?id=135767 (accessed on January 8, 2007) (2 pages)
	BK	Media Release: "Nautilus Biotech Announces Progress on Belerofon, an Improved IFNalpha With Single Amino Acid Sequence Change, Designed to Reduce Frequency of Injection for Hepatitis C Chronic Infection and Cancer" Paris, France March 23, 2004 http://www.prnewswire.co.uk/cgi/news/release?id=119794 (accessed on January 8, 2007) (2 pages)
	BL	Media Release: "Nautilus Biotech receives FDA approval for Phase 1 clinical trial in the USA for oral Belerofon®, its long-lasting, Interferon-alpha drug", Paris, France May 14, 2007 http://www.nautilusbiotech.com/news_100507.html (accessed on May 18, 2007) (3 pages)

Examiner Signature /Elly Gerald Stoica/	Date Considered 11/20/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EGS/

Sheet 3 of 3

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-012001 / 922		Application No. 10/658,834	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Rene Gantier et al.			
				Filing Date September 8, 2003		Group Art Unit 1631	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
	BM	Media Release: "Nautilus Biotech: 'Next Generation Biopharmaceuticals (NGB)'" Paris, France June 21, 2004 http://www.prnewswire.co.uk/cgi/news/release?id=125241 (accessed on January 8, 2007) (1 page)					
	BN	Media Release: "Nautilus Biotech and HanAll Pharmaceutical Announce License Agreement to Develop Three Nautilus Biotech Products in South Korea," Paris, France, 03/06/07, http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-06-2007/0004540099&EDATE= (accessed on 03/16/07) (3 pages).					
	BO	Media Release: "Nautilus Biotech announces IND filing for Belerofon [®] , its oral, long-lasting, Interferon-alpha drug," Paris, France, 02/27/07, http://www.nautilusbiotech.com/news_270207.html (accessed on 03/16/07) (3 pages).					
	BP	Media Release: "Nautilus Biotech Announces IND Filing for its Injectable Long-Lasting INTERFERON-alpha, BELEROFON(R)" Paris, France October 10, 2006 http://www.prnewswire.co.uk/cgi/news/release?id=181151 (accessed on January 8, 2007) (2 pages)					
	BQ	Media Release: "Nautilus Biotech begins Phase I clinical trial in the USA for subcutaneous Belerofon [®] , its long-lasting, Interferon-alpha drug," Paris, France, 04/02/07, http://www.nautilusbiotech.com/news_020407.html (accessed on 04/09/07) (3 pages).					
	BR	Runkel et al., "Differences in activity between α and β type I interferons explored by mutational analysis," <i>Journal of Biological Chemistry</i> , 273: 8003-8008, (1998).					
	BS	Vega, M., "Improving the Delivery and Pharmacokinetics of Therapeutic Proteins by Increased Resistance to Proteolysis" (Meeting Abstract) <i>Second Annual Advancing Protein Therapeutics, Engineering the Next Generation of Proteins for Therapeutics</i> (January 12, 2006) http://www.chi-peptalk.com/pttn2006.asp					
	BT	Vega, M., "Next-Generation Protein Therapeutics for Oral Delivery" (Meeting Abstract) <i>Third Annual Optimizing Protein and Antibody Therapeutics, Pioneering New Frontiers</i> (January 9, 2007) http://www.chi-peptalk.com/06_PTT.asp					

Examiner Signature /Elly Gerald Stoica/	Date Considered 11/20/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EGS/